Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acceleron Pharma (XLRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,929,356
  • Shares Outstanding, K 46,190
  • Annual Sales, $ 13,480 K
  • Annual Income, $ -108,450 K
  • 36-Month Beta 1.38
  • Price/Sales 139.67
  • Price/Cash Flow N/A
  • Price/Book 6.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.67
  • Number of Estimates 5
  • High Estimate -0.60
  • Low Estimate -0.77
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -8.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.42 +10.52%
on 01/29/19
44.45 -4.48%
on 02/12/19
-1.46 (-3.32%)
since 01/15/19
3-Month
38.42 +10.52%
on 01/29/19
56.91 -25.39%
on 12/03/18
-8.20 (-16.19%)
since 11/15/18
52-Week
32.53 +30.53%
on 06/28/18
59.59 -28.75%
on 09/21/18
-0.01 (-0.02%)
since 02/15/18

Most Recent Stories

More News
Acceleron to Present at Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases,...

XLRN : 42.46 (+1.65%)
Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.

CELG : 90.69 (+0.01%)
BLUE : 137.03 (+2.04%)
XLRN : 42.46 (+1.65%)
BMY : 51.67 (+1.65%)
Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?

Investors are looking forward to Revlimid's performance and updates from the recently announced merger agreement when Celgene Corporation (CELG) reports Q4 results.

CELG : 90.69 (+0.01%)
VRTX : 188.07 (+1.27%)
XLRN : 42.46 (+1.65%)
BMY : 51.67 (+1.65%)
Acceleron Pharma Falls 3.91% on Heavy Volume: Watch For Potential Rebound

Acceleron Pharma (NASDAQ:XLRN) traded in a range yesterday that spanned from a low of $40.01 to a high of $40.18. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of...

XLRN : 42.46 (+1.65%)
Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marathon Petroleum Corporation...

MPC : 65.15 (+1.73%)
NTRA : 16.55 (+2.35%)
JBLU : 17.96 (-0.66%)
WAAS : 21.26 (+0.85%)
AMC : 13.79 (+1.03%)
XLRN : 42.46 (+1.65%)
Acceleron Announces Pricing of Public Offering of Common Stock

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic,...

XLRN : 42.46 (+1.65%)
Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that...

XLRN : 42.46 (+1.65%)
CELGZ : 0.91 (+7.06%)
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline

Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

CELG : 90.69 (+0.01%)
BLUE : 137.03 (+2.04%)
XLRN : 42.46 (+1.65%)
BMY : 51.67 (+1.65%)
Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that...

JPM : 105.55 (+3.06%)
XLRN : 42.46 (+1.65%)
Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for "Best of ASH" by the American Society of Hematology

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes...

XLRN : 42.46 (+1.65%)
CELGZ : 0.91 (+7.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade XLRN with:

Business Summary

Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 43.50
1st Resistance Point 42.98
Last Price 42.46
1st Support Level 41.65
2nd Support Level 40.84

See More

52-Week High 59.59
Fibonacci 61.8% 49.25
Fibonacci 50% 46.06
Fibonacci 38.2% 42.87
Last Price 42.46
52-Week Low 32.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar